• Forum Think Finance - Bolsa e Forex »
• Perfil de Nuno »
• Mostrar Mensagens »
• Tópicos

Hemispherx BioPharma, Inc (NYSEMKT:HEB)’s shares gained 15.14% and closed at $0.36. The company on Sept. 29 announced a widened set of research collaborations designed to develop therapeutic cocktails against Ebola which may potentially overcome the emergence of drug resistance due to Ebola virus mutation. The rapid acquisition of Ebola virus (EBOV) sequence variation has been recently demonstrated during genomic surveillance of the current Ebola virus disease (EVD). This observed genomic sequence variation suggests drugs that target specific viral non-variant protein sequences are at risk of mutation mediated activity failure (Science (2014) 345:1369).